A whole‐genome sequencing study of 102 pancreatic NET patients by Scarpa et al reported novel pathogenic mutations in DNA repair genes MUTYH, CHEK2 and BRCA2, which are well‐known breast cancer susceptibility genes.10 However, NET are not incorporated into genetic testing guidelines for breast cancer patients.11 Recently, a SEER database retrospective study12 showed that the incidence of pancreatic NET is higher in patients with a first primary cancer of the pancreas, bladder, thymus and female breast cancer. This evidence concerns the gene CHEK2 and pancreatic neuroendocrine tumor.